Arrowhead reports interim Phase 1/2a ARO-MAPT data
The company says clinical data in healthy volunteers demonstrated deep and durable tau reductions.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
5 results loaded, newest first. End of these results.
Arrowhead Pharmaceuticals Announces ARO — MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers
For best results when printing this announcement, please click on link below: Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers Arrowhead’s TRiM(™) platform achieves clinical validation for delivery of siRNA that crosses the
Arrowhead Reports Up to 85% CSF Tau Reduction in Phase 1/2a
Interim data showed subcutaneous ARO-MAPT reduced CSF total tau by a mean of up to 73% at Day 105, with a maximum reduction of 85%, in healthy volunteers. The drug was generally well tolerated.
Arrowhead Reports Interim Phase 1/2a Data for ARO-MAPT
Arrowhead Pharmaceuticals announced interim results from an ongoing Phase 1/2a study of its investigational RNAi therapy ARO-MAPT, reporting deep and durable tau reductions in healthy volunteers.
Arrowhead Pharmaceuticals to host webinar on interim ARO-MAPT clinical data
The webinar is scheduled for Wednesday, October 14, 2026 at 11:30 AM PDT and will focus on investigational therapy ARO-MAPT and Arrowhead's CNS pipeline. It will include interim results from the Phase 1/2a AROMAPT-SC-1001 study.